Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > S-Glycoprotein B (HSV-2)

S-Glycoprotein B (HSV-2)

Brief Information

Name:Envelope glycoprotein B, gB
Target Synonym:UL55
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product Inquiry

* We couldn't find what you're looking for. You can let us help by filling the form below. Our tech team will get back to you shortly.
* This form is only used to collect product demand consultation. All the information will be kept strictly confidential.
Product inquiry collection form
*
*
*
*
*
*
*
*
*
ACRO Quality

Synonym Name

gB

Background

Epstein-Bar Virus (EBV), also known as human herpesvirus 4, belongs to gamma herpes virus family and is a very common human virus worldwide. EBV causes infectious mononucleosis (IM) and also associates to some specific types of cancers such as Burkitt’s lymphoma (BL) and gastric carcinoma (GC). Glycoprotein B (gB) plays an important role in viral entry by binding with αvβ6/αvβ8 integrins to trigger the membrane fusion and entry process of epithelial cells, which makes it become an great target for EBV research.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Fiztasovimab NPC-21 Phase 2 Clinical Nobelpharma Co Ltd Cytomegalovirus Infections Details
TRL-345 CMV-345; TRL-345 Phase 1 Clinical Trellis Bioscience LLC Cytomegalovirus Infections Details
Fiztasovimab NPC-21 Phase 2 Clinical Nobelpharma Co Ltd Cytomegalovirus Infections Details
TRL-345 CMV-345; TRL-345 Phase 1 Clinical Trellis Bioscience LLC Cytomegalovirus Infections Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message